Pharma BD Deal Intelligence
Gilead strikes $2.48 billion deal with Nurix to focus on protein degradation using DELigase platform for up to five therapeutic programs in cancer.
Gilead elected to extend the 2019 collaboration research term by two years; Nurix received a $15M extension fee and remains eligible for up to…
Q1 FY2026 update: Gilead continues to advance the IRAK4 degrader GS-6791 in an ongoing first-in-human Phase 1 healthy-volunteer study; Nurix retains a 50/50 US…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
In June 2019 Gilead Sciences entered a strategic collaboration licensing Nurix Therapeutics' DELigase targeted protein degradation platform to discover and develop E3-ligase-based degrader therapies across up to five targets in cancer and other diseases. Nurix received a $45 million upfront payment and is eligible for up to ~$2.3 billion in research, preclinical, clinical, regulatory and commercialization milestones, plus a co-develop/co-detail option on up to two US programs. The alliance has matured into the inflammation space: in April 2024 Gilead exercised its option to extend the research term by two years ($15M extension fee), and in April 2025 the FDA cleared the IND for the lead program GS-6791 (formerly NX-0479), an oral IRAK4 degrader for inflammatory conditions including rheumatoid arthritis and atopic dermatitis; Gilead began a Phase 1 healthy-volunteer study in Q2 2025 and continues to advance it as of Q1 2026. The $5M IND-clearance milestone brought Nurix's cumulative receipts under the 2019 agreement to $135 million, with ~$420M in IRAK4-specific milestones still outstanding. NX-5948 (bexobrutideg), Nurix's BTK degrader, is wholly owned and NOT part of the Gilead collaboration.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Nurix Therapeutics Inc. (this deal) | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2019 deals · Gilead Sciences Inc. deals · Immunology deals